Perrigo (NYSE:PRGO) is scheduled to announce its earnings results before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of $1.23 per share for the quarter.
Shares of Perrigo (PRGO) opened at $88.25 on Monday. Perrigo has a 1-year low of $63.68 and a 1-year high of $95.93. The company has a current ratio of 1.72, a quick ratio of 1.24 and a debt-to-equity ratio of 0.54. The firm has a market cap of $12,430.00, a P/E ratio of -9.63, a price-to-earnings-growth ratio of 1.88 and a beta of 0.66.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 20th. Shareholders of record on Friday, March 2nd will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.86%. This is a positive change from Perrigo’s previous quarterly dividend of $0.16. The ex-dividend date is Thursday, March 1st. Perrigo’s payout ratio is presently -6.99%.
A number of research firms have recently commented on PRGO. Cantor Fitzgerald set a $107.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research note on Saturday, December 16th. Argus raised shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a research note on Friday, December 8th. Finally, Canaccord Genuity set a $100.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research note on Tuesday, December 26th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $93.47.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.